Nordis, the legal victory embraces many compound medications

Novo Nordsk He scored a great legal victory that greatly restricts pharmacies from marketing or selling cheaper and non -approved versions of pharmaceutical factories subject to drug weight and diabetes treatment.

A federal judge in Texas late Thursday rejected an offer by doubling pharmacies to maintain copies of OzemPIC and Wegovy while the legal challenge is revealed about the lack of these drugs. This came in response to the February lawsuit from a commercial group guaranteed against food and drug identification that the active component in these drugs, the pillar, is no longer shorter in the United States

Patients have flocked to cheaper versions when OzemPIC and Wegovy have been in default over the past two years due to high demand, or if they do not have insurance coverage of expensive treatments.

during FDA-DecledPharmacists can make vehicle versions of brand medications. Many health care companies, such as To shake and breatheAs these copies were presented. But drug makers and some health experts have pushed back against this practice because the Food and Drug Administration does not agree on complex medications, which are mainly copies made specifically by the doctor to meet the needs of a specific patient.

“We are happy that the court rejected the attempts of the compounds to undermine the decision of the Data -based Food and Drug Administration that the deficiency” in the hunglotide “.

He said, referring to more than 100 lawsuits against compound pharmacies and other entities through 32 states: “Patient safety is still a top priority for Novo Nordisk and extensive legal measures at the country level that we have taken to protect Americans from the health risks offered by illegal Semaglutide drugs,” referring to more than 100 lawsuits against compound pharmacies and other entities across 32 states.

On Thursday, the American boycott judge, Mark Beatman, denied the presentation of the Association for the Use of External Sources to obtain a preliminary judicial order that would prevent the Food and Drug Administration from taking action against its members to take copies of the calls.

This decision is previously determined to the Food and Drug Administration (FDA) that the deficiency of the semules in the United States has ended and means that the FDA can now follow the so -called 503A pharmacies that make vehicle copies of the semiotide according to the individual recipes of a specific patient.

These pharmacies are largely organized by countries instead of the Food and Drug Administration.

These pharmacies make vehicle drugs according to the individual prescriptions of a specific patient and are largely organized by countries instead of the Food and Drug Administration.

The decision also means that the FDA can start targeting federal 503B pharmacies, which make compound medicines in large quantities with or without prescriptions, after May 22. The agency’s behavior can include product attacks and warning messages to pharmacies.

On Thursday, the decision follows another victory for Nofu Nordsk. A different federal judge ruled in Texas earlier this week for the pharmaceutical maker against 503A Pharmacy, Medioak Pharmacy, permanently prohibiting the company from marketing or selling compound hoodyd.

Novo Nordsk and Eli Lily They fractured strongly on the pharmacies that are joined over the past two years because they benefit from the popularity of weight loss and diabetes drugs.

Elie Lily has passed A similar legal process With tirzepatide, the active ingredient in the drug loss of Zepbound and the treatment of Mounjaro diabetes. The FDA (FDA) has announced that the American shortage in Terzopatid during the past year, prompting the same commercial group the complex to prosecute the Food and Drug Administration over the drug.

In March, a federal judge refused to request the group of a preliminary judicial order regarding the enforcement of the Food and Drug Administration against its members to create copies of mounjaro and Zepbound. The vehicle has resumed.